Status:
COMPLETED
Feasibility Study of the Advanced Symptom Management System (ASyMS) in Canadian Cancer Patients
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Supportive Care
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The Advanced Symptom Monitoring and Management System - Canada (ASyMS-Can) is a remote phone-based symptom management system that prompts patient self-care and clinician telephone triage and intervent...
Detailed Description
In addition, patients can access a self-care library and symptom graphs (detailing trends in individual symptoms experienced) through the ASyMS-Can patient phones. If the incoming symptom reports are ...
Eligibility Criteria
Inclusion
- Patients diagnosed with early stage breast, colorectal, and lymphoma (Hodgkin's \[HD\], non- Hodgkin's \[NHL\].
- Scheduled to receive 2-, 3- or 4-weekly chemotherapy protocols (i.e. chemotherapy administered at repeated cycles of 14, 21 or 28 days, respectively).
- Scheduled to receive a minimum of 3 cycles of systemic chemotherapy (any regimen); adjuvant or neo-adjuvant on an out-patient basis;
- Adults \>=18 years of age;
- Able to provide written consent and willing to participate;
- Adequate ability to use or be trained in use of a mobile phone for symptom reporting
Exclusion
- Enrolled/receiving an investigational treatment;
- Scheduled to receive concurrent radiotherapy during chemotherapy treatment.
- Scheduled to receive weekly chemotherapy protocols. In addition, patients who shift from a 2-, 3- or 4-weekly protocol to a weekly protocol during chemotherapy will be excluded from further participation in the study.
- Any distant metastasis based on Ann Arbor or TNM staging
- Unable to speak/read/write English sufficiently to complete study measures.
- Unable to complete study measures due to a pre-existing disability (e.g. visually impaired)
- Cognitive impairment/severe pre-existing emotional issues as assessed by the treatment team which may impede completion of study measures.
- Low performance status (ECOG \> or =3)
Key Trial Info
Start Date :
November 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2019
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03335189
Start Date
November 15 2017
End Date
May 28 2019
Last Update
June 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada